Here’s why a cancer-testing startup agreed to a $2.1B buyout

Cancer blood test developer Thrive Earlier Detection Corp. has made large strides since its launch last year, raising nearly $370 million from investors and presenting some of the most stringent clinical trial data in the field. So why agree to a buyout now? Read More

Read More

Eaton Vance closes acquisition of Florida firm

Eaton Vance Corp., one of Boston’s largest public companies, this week completed its acquisition of the assets of Florida-based WaterOak Advisors LLC, which has $2.3 billion in client assets under management. Read More

Read More